Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Mahidol University
Modality
Cell therapy
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01833585CT.gov Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atherosclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Blood Mononuclear Cell (this asset) | Mahidol University | P3 | B · 62 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Simvastatin | Northern California Institute of Research and Education | P4 | BBB |
| Atorvastatin | Erasmus Medical Center | P4 | BB |
| Clopidogrel | Ewha Womans University Seoul Hospital | P4 | BB |
| Cilostazol | Asan Medical Center | P4 | BB |
| Rosuvastatin | Emory University | P4 | BB |
| Ezetimibe | paresh Dandona | P4 | BB |
| Testosterone Undecylate | Brigham and Women's Hospital | P4 | BB |
+37 more in the Atherosclerosis cohort
Other indications for Peripheral Blood Mononuclear Cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ulcer Of Lower Limbs | — | P3 | BB · 64 |
| Amyotrophic Lateral Sclerosis | — | P2 | B · 58 |
| Glioblastoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Peripheral Blood Mononuclear Cell in Atherosclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/peripheral-blood-mononuclear-cell-atherosclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →